Welcome to our dedicated page for Compass Therapeutics SEC filings (Ticker: CMPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Compass Therapeutics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing proprietary antibody-based therapeutics. Its SEC reports include Form 8-K disclosures for operating and financial results, Regulation FD updates, clinical data presentations and other material events related to tovecimig and the broader antibody pipeline.
The company’s definitive proxy materials cover annual meeting matters, director elections and stockholder voting procedures. Filing disclosures also address governance, equity compensation, capital-structure matters, cash resources, clinical and regulatory risk areas, and the public-company controls associated with a Nasdaq-listed development-stage biotechnology issuer.
Biotechnology Value Fund and related entities reported beneficial ownership of Compass Therapeutics common stock. As of the close of business on March 31, 2026, the filing shows BVF beneficially owned 4,142,020 shares and BVF2 beneficially owned 3,028,951 shares. The statement uses the issuer's disclosed shares outstanding of 180,087,915 shares as of February 27, 2026 to calculate percentages. The filing lists shared voting and dispositive power figures across affiliated entities and includes customary disclaimers of beneficial ownership among group members.
Compass Therapeutics (CMPX) reported a deeper quarterly loss while strengthening its balance sheet and advancing its lead cancer drug. For the three months ended March 31, 2026, net loss was $18.3 million versus $16.6 million a year earlier, driven mainly by higher general and administrative expenses of $6.9 million, including increased stock-based compensation, while research and development spending was relatively stable at $13.4 million.
Cash, cash equivalents and marketable securities totaled $195 million, and the company believes this will fund operations into 2028. In its oncology pipeline, tovecimig showed statistically significant improvement in overall response rate in second-line biliary tract cancer in a Phase 2/3 study and received FDA Orphan Drug Designation, and the company plans to meet with the FDA ahead of a potential BLA submission.
Compass Therapeutics reported first quarter 2026 results and highlighted major progress in its oncology pipeline. Net loss was $18.3 million, or $0.10 per share, compared with $16.6 million, or $0.12 per share, for the same period in 2025. Cash and marketable securities totaled $195 million as of March 31, 2026, which the company expects will fund operations into 2028.
Tovecimig plus paclitaxel in second-line biliary tract cancer achieved an overall response rate of 17.1% versus 5.3% for paclitaxel alone and improved median progression-free survival to 4.7 months versus 2.6 months (HR=0.44, p<0.0001). Tovecimig received Orphan Drug Designation, and the company plans a BLA submission later in 2026. Early signals from CTX-8371 and CTX-10726, along with planned CTX-471 Phase 2 work, underscore a broad bispecific antibody pipeline.
Compass Therapeutics, Inc. Chief Accounting Officer Neil Lerner reported an open-market purchase of common stock. On April 29, 2026, he bought 15,000 shares at $1.89 per share. Following this transaction, he directly holds 397,500 common shares.
His holdings include 62,500 unvested restricted stock units granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock and vests in four equal annual installments starting January 2, 2027.
Compass Therapeutics General Counsel Jonathan Anderman purchased 25,000 shares of common stock in an open-market transaction at $1.89 per share. After this buy, he directly holds 196,000 shares. 150,000 of these shares are unvested restricted stock units granted on January 2, 2026, which vest in four equal annual installments starting January 2, 2027, subject to service-based vesting conditions.
Compass Therapeutics, Inc. reported that its General Counsel, Jonathan Anderman, received a grant of 25,000 shares of common stock at an award value of $1.89 per share as equity compensation. Following this grant, he holds 196,000 shares in total.
The filing notes that 150,000 of these shares are unvested restricted stock units granted on January 2, 2026. Each RSU converts into one share of common stock if service-based vesting conditions are met, vesting in four equal annual installments starting January 2, 2027.
Lerner Neil reported acquisition or exercise transactions in this Form 4 filing.
Compass Therapeutics, Inc. Chief Accounting Officer Neil Lerner received a grant of 15,000 shares of common stock at $1.89 per share on April 29, 2026, increasing his direct holdings to 397,500 shares. A footnote notes that 62,500 of these shares are unvested restricted stock units granted on January 2, 2026, which vest in four equal annual installments starting January 2, 2027 under service-based conditions.
Compass Therapeutics has called its 2026 Annual Meeting for June 10, 2026 as a virtual-only event, open to stockholders of record as of April 15, 2026. Holders of 180,087,915 common shares may vote online, by phone, or by mail.
Stockholders will elect two Class III directors, vote on ratifying CohnReznick LLP as auditor for 2026, and cast non-binding advisory votes on 2025 executive pay and how often future “Say‑on‑Pay” votes should occur, with the board recommending an annual frequency.
The filing details board and committee structures, updated 2026 director retainers and option grants, and 2025 compensation for key executives, including total pay of $5.10 million for CEO Thomas J. Schuetz, $1.39 million for CFO Barry Shin, and $1.43 million for General Counsel Jonathan Anderman.
Compass Therapeutics reported detailed results from its randomized Phase 2/3 COMPANION-002 study of tovecimig plus paclitaxel in second-line biliary tract cancer. In 168 patients randomized 2:1, the combination improved overall response rate to 17.1% versus 5.3% for paclitaxel alone, meeting the primary endpoint with statistical significance (p=0.031).
The key secondary endpoint of median progression-free survival also favored tovecimig, with 4.7 months versus 2.6 months for control (hazard ratio 0.44, p<0.0001), based on blinded independent central review. Overall survival analyses did not meet statistical significance because 54% of control patients crossed over to receive tovecimig; these crossover patients showed median overall survival of 12.8 months versus 6.1 months for non-crossover patients (hazard ratio 0.54, p=0.04).
The company stated that tovecimig was generally well tolerated, with a safety profile consistent with prior studies, and noted that 85% of trial participants received the combination. Compass intends to meet with the U.S. FDA in the coming months to discuss the data in advance of a planned Biologics License Application submission for tovecimig in this setting.